Telix Pharmaceuticals Limited, A Biopharmaceutical Company, Announces That It Has Dosed The Final Patient And Completed Recruitment Into The Phase Iii Pivotal Study Zircon (Zirconium In Renal Cancer Oncology, Nct03849118) Of Its Investigational Renal (Kidney) Cancer Imaging Agent Tlx250-Cdx (89Zr-Dfo-Girentuximab). This Global Study Has Dosed 300 Patients To Date, Exceeding The Target Enrolment Of 252 Patients, Announced On 8 March 2022.Tlx250-Cdx, Which Has Received
